

- Ongoing, prospective, open label, non-comparative, multicentre, long-term phase IV study examining the efficacy and safety of recombinant human growth hormone in short children born small for gestational age (SGA) (n=278)
- First interim analysis of patients who have completed 1 year of treatment
- None of the children developed diabetes mellitus within the first year of treatment
- Treatment with recombinant human growth hormone was effective, as documented by all height parameters
- Most adverse events were of mild-to-moderate intensity and the majority were unrelated to study treatment

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Sandoz Biopharmaceuticals. Medical writing assistance for this study was provided by Tony Reardon of Spirit Medical Communications Ltd . For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).